Northwest Biotherapeutics (NWBO) Research & Development (2010 - 2026)

Northwest Biotherapeutics' Research & Development history runs 17 years deep, the most recent figure standing at $4.9 million for Q1 2026.

• On a quarterly basis, Research & Development fell 41.83% year-over-year to $4.9 million in Q1 2026; TTM through Mar 2026 was $25.3 million, a 28.35% decrease from a year earlier, with the FY2025 full-year figure at $28.8 million, down 17.49% from the prior year.
• Research & Development slipped to $4.9 million in Q1 2026 per NWBO's latest filing, from $5.6 million in the prior quarter.
• Across five years, Research & Development topped out at $13.6 million in Q2 2022 and bottomed at $4.8 million in Q1 2022.
• The 5-year median for Research & Development is $7.5 million (2023), against an average of $7.8 million.
• Across the five-year window, Research & Development soared 150.32% in 2022 and tumbled 54.46% in 2023, its largest moves.
• Year by year, Research & Development stood at $9.4 million in 2022, then decreased by 20.3% to $7.5 million in 2023, then surged by 41.17% to $10.5 million in 2024, then plunged by 47.22% to $5.6 million in 2025, then fell by 12.53% to $4.9 million in 2026.
• Per Business Quant, the three latest NWBO Research & Development figures stand at $4.9 million (Q1 2026), $5.6 million (Q4 2025), and $7.4 million (Q3 2025).